A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Post Prandial Distress Syndrome
Interventions
DRUG

Placebo

2 Placebo tablets, TID, orally, 58 days

DRUG

20 mg ATI 7505

1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days

DRUG

40 mg ATI 7505

1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days

DRUG

80 mg ATI 7505

2 ATI 40mg tablets, TID, orally, 58 days

Trial Locations (64)

11021

Research Facility, Great Neck

11023

Research Facility, Great Neck

11042

Research Facility, Lake Success

11214

Research Facility, Brooklyn

13210

Research Facility, Syracuse

15010

Research Facility, Beaver Falls

22601

Research Facility, Winchester

27103

Research Facility, Winston-Salem

28304

Research Facility, Fayetteville

29414

Research Facility, Charleston

29621

Research Facility, Anderson

30263

Research Facility, Newnan

31405

Research Facility, Savannah

32256

Research Facility, Jacksonville

32720

Research Facility, DeLand

32806

Research Facility, Orlando

33021

Research Facility, Hollywood

33156

Research Facility, Miami

33426

Research Facility, Boynton Beach

33777

Research Facility, Largo

34652

Research Facility, New Port Richey

37403

Research Facility, Chattanooga

37404

Research Facility, Chattanooga

45242

Research Facility, Cincinnati

45440

Research Facility, Dayton

47714

Research Facility, Evansville

48235

Research Facility, Detroit

53209

Research Facility, Milwaukee

61107

Research Facility, Rockford

66606

Research Facility, Topeka

71201

Research Facility, Monroe

73104

Research Facility, Oklahoma City

73112

Research Facility, Oklahoma City

76034

Research Facility, Colleyville

80120

Research Facility, Littleton

84124

Research Facility, Salt Lake City

90015

Research Facility, Los Angeles

90045

Research Facility, Los Angeles

91710

Research Facility, Chino

92108

Research Facility, San Diego

92691

Research Facility, Mission Viejo

93721

Research Facility, Fresno

94070

Research Facility, San Carlos

97520

Research Facility, Ashland

N1H 3R3

Research Facility, Guelph

L8N 3Z5

Research Facility, Hamilton

L8N 4A6

Research Facility, Hamilton

G6V 3Z1

Research Facility, Lévis

J4N 1E1

Research Facility, Longueuil

H1T 2M4

Research Facility, Montreal

K1H 8L6

Research Facility, Ottawa

G1L 3L5

Research Facility, Québec

G1R 2J6

Research Facility, Québec

G1S 4L8

Research Facility, Québec

J6E 6J2

Research Facility, Saint-Charles-Borromée

M3N 2V7

Research Facility, Toronto

B9 5SS

Research Facility, Birmingham

CF14 4XW

Research Facility, Cardiff

CV2 2DX

Research Facility, Coventry

CW1 4QJ

Research Facility, Crewe

NW3 2QG

Research Facility, London

NR4 7UY

Research Facility, Norwich

BR6 8ND

Research Facility, Orpington

M6 8HD

Research Facility, Salford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

ARYx Therapeutics

INDUSTRY

lead

Procter and Gamble

INDUSTRY

NCT00630370 - A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome | Biotech Hunter | Biotech Hunter